Ashland Q3 Sales Rise 7%, Net Leverage Hits Target, Full-Year Outlook Reaffirmed
ASH sits 47% above its 52-week low of $46.295.
Summary
Ashland reported Q3 sales of $497M, up 7% year-over-year, with growth across all business units and regions. Net income swung to a $16M profit from a $742M loss a year ago, while Adjusted EBITDA of $109M was down slightly from $113M. The company reaffirmed its full-year sales outlook of $1.835B-$1.87B and Adjusted EBITDA guidance of $385M-$400M, signaling confidence despite lingering production and cost pressures. Net leverage improved to 2.4x, returning to the long-term target range and strengthening financial flexibility. This follows a period of activist investor activity, with Ancora and Cruiser pushing for strategic changes, making the reaffirmed guidance and operational progress a positive signal. The results show broad-based demand and commercial execution, with Life Sciences delivering double-digit growth and Personal Care maintaining momentum, while cash flow remained healthy at $121M from operations.
At the time of this announcement, ASH was trading at $68.01 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $46.30 to $72.25. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.